KARPAS 299 Human Non-Hodgkin’s Ki-positive Large Cell Lymphoma cell line useful in oncology research, developed at the University of Cambridge.
Publications:
Ficsher et al. (1988). Blood 72, 234–240
Wolke et al. (2006). Int J Mol Med 17, 275–278
Drexler et al. (2004). Leukemia 18, 1569–1571
Fillmore et al. (2002). FEBS Lett. 522, 183-188
Cambridge Enterprise Limited is the exclusive licensor for the Karpas cell line portfolio. We have partnered with ECACC (The European Collection of Cell Cultures; a Public Health England Culture Collection) to manage distribution of the majority of these cells on our behalf. Enquires to either organisation are welcomed.
To find out more about how this website collects your personal data see www.enterprise.cam.ac.uk/about-us/information-compliance/data-protection/core-privacy-notices/website-users-use-personal-information/